Carna Biosciences is a clinical-stage company focused on discovering and developing small molecule drugs targeting oncology and autoimmune diseases. Carna’s pipeline includes a non-covalent BTK inhibitor for dermatology and nephropathy, a potential first-in-class STING antagonist for immune disorders, a next-generation wild-type & pan-mutant BTK inhibitor for CLL, and a potential first-in-class CDC7 inhibitor for blood cancers. 

Carna is actively seeking strategic partners to accelerate the clinical development of our pipeline.

(1) Sofnobrutinib (Ph 2-ready): non-covalent BTK inhibitor for dermatology and nephropathy

(2) AS-5908 (preclinical): potential first-in-class oral STING antagonist for immune disorders

(3) Docirbrutinib (Ph 1b): next-generation wild & pan-mutant BTK inhibitor for CLL (AS-1763)

(4) Monzosertib (Ph 1): potential first-in-class CDC7 inhibitor for blood cancers